{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:49:41Z","timestamp":1792712981326,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,2,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Activation of the platelet-derived growth factor (PDGF) and c-kit receptors has been proposed as important in mediating the growth of AIDS-related Kaposi's sarcoma (KS). We investigated the response of KS to the PDGF receptor (PDGFR)\/c-kit inhibitor, imatinib mesylate, and investigated the effect of this therapy on critical signal transduction intermediates. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Ten male patients with AIDS-related cutaneous KS, which progressed despite chemotherapy and\/or highly active antiretroviral therapy, received imatinib mesylate administered orally, 300 mg twice daily. Clinical response was determined by serial tumor measurements. To determine biologic and histologic response, skin lesion biopsies were obtained at baseline and following 4 weeks of therapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Five of 10 participants had a partial response by tumor measurements. Biopsies after 4 weeks of therapy demonstrated histologic regression in four of six patients. Four patients' tumor biopsies were assessable for immunohistochemistry end points pre- and post-therapy. These demonstrated inhibition of PDGFR and its downstream effector, extracellular receptor kinase, which is a member of the mitogen-activated protein kinase family. The most common adverse event was diarrhea, which led to dose reduction in six patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Imatinib mesylate administered orally twice daily for AIDS-related KS results in clinical and histologic regression of cutaneous KS lesions within 4 weeks. These promising results demonstrate that inhibition of the c-kit and\/or PDGF receptors may represent an effective strategy for treating KS. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.06.079","type":"journal-article","created":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T01:25:39Z","timestamp":1101864339000},"page":"982-989","source":"Crossref","is-referenced-by-count":140,"title":["Imatinib-Induced Regression of AIDS-Related Kaposi's Sarcoma"],"prefix":"10.1200","volume":"23","author":[{"given":"Henry B.","family":"Koon","sequence":"first","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Bubley","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Pantanowitz","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Masiello","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Crosby","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Proper","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Weeden","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Miller","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Chatis","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill J.","family":"Egorin","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Tahan","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Dezube","sequence":"additional","affiliation":[{"name":"From the Beth Israel Deaconess Medical Center; PerkinElmer Life Sciences, Boston; Cell Signaling Technology, Beverly, MA; and University of Pittsburgh Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"BIB1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0795-707"},{"key":"BIB2","unstructured":"Danzig JB, Brandt LJ, Reinus JF, et al: Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol 86:715,1991-718,"},{"key":"BIB3","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(96)80019-9"},{"key":"BIB4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.3.979"},{"key":"BIB5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.11.4068"},{"key":"BIB6","doi-asserted-by":"publisher","DOI":"10.1126\/science.2643161"},{"key":"BIB7","doi-asserted-by":"crossref","unstructured":"Miles SA: Kaposi sarcoma: A cytokine-responsive neoplasia? Cancer Treat Res 63:129,1992-140,","DOI":"10.1007\/978-1-4615-3088-6_6"},{"key":"BIB8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.15.7046"},{"key":"BIB9","unstructured":"Cornali E, Zietz C, Benelli R, et al: Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 149:1851,1996-1869,"},{"key":"BIB10","unstructured":"Sturzl M, Brandstetter H, Zietz C, et al: Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: A combined in vitro and in vivo analysis. Oncogene 10:2007,1995-2016,"},{"key":"BIB11","unstructured":"Roth WK, Werner S, Schirren CG, et al: Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture. Oncogene 4:483,1989-487,"},{"key":"BIB12","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.16.8383-8399.2002"},{"key":"BIB13","doi-asserted-by":"publisher","DOI":"10.1046\/j.0303-6987.2004.0132.x"},{"key":"BIB14","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(98)70302-1"},{"key":"BIB15","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90534-0"},{"key":"BIB16","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80388-X"},{"key":"BIB17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2269"},{"key":"BIB18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203418"},{"key":"BIB19","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(20000301)76:3<354::AID-JCB2>3.0.CO;2-U"},{"key":"BIB20","doi-asserted-by":"publisher","DOI":"10.3109\/08977199809017484"},{"key":"BIB21","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.5.8136"},{"key":"BIB22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.52.32966"},{"key":"BIB23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"BIB24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"BIB25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.027"},{"key":"BIB26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025217"},{"key":"BIB27","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00206-X"},{"key":"BIB28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1201"},{"key":"BIB29","unstructured":"Remick SC, Ramanathan RK, Mulkerin D, et al: A Phase I Pharmacokinetic Study of STI-571 in Patients with Advanced Malignancies and Varying Degrees of Renal Dysfunction. Proc Am Soc Clin Oncol 22:503a,2003,"},{"key":"BIB30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"BIB31","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4644(20010501)81:2<304::AID-JCB1045>3.0.CO;2-U"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.06.079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:34:27Z","timestamp":1653510867000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.06.079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,10]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,2,10]]}},"alternative-id":["10.1200\/JCO.2005.06.079"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.06.079","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,10]]}}}